Nuvalent, Inc. financial data

Symbol
NUVL on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Broadway, 14 Th Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.12K % +2.11%
Debt-to-equity 5.46 % +8.98%
Return On Equity -28.6 % -8.2%
Return On Assets -27.1 % -7.74%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 1.1B USD +360%
Weighted Average Number of Shares Outstanding, Basic 65.7M shares +15%
Weighted Average Number of Shares Outstanding, Diluted 65.7M shares +15%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 184M USD +83%
General and Administrative Expense 56.6M USD +77.7%
Operating Income (Loss) -241M USD -81.7%
Nonoperating Income (Expense) 16.8M USD -8.14%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -84.3M USD -151%
Income Tax Expense (Benefit) 40K USD
Net Income (Loss) Attributable to Parent -224M USD -96.6%
Earnings Per Share, Basic -3.48 USD/shares -70.6%
Earnings Per Share, Diluted -3.48 USD/shares -70.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 369M USD +318%
Marketable Securities, Current 799M USD +146%
Assets, Current 1.18B USD +181%
Other Assets, Noncurrent 9.18M USD +73%
Assets 1.19B USD +180%
Accounts Payable, Current 15.9M USD +62.9%
Employee-related Liabilities, Current 6.83M USD +52.9%
Accrued Liabilities, Current 35.2M USD +82.2%
Liabilities, Current 51.1M USD +75.7%
Liabilities 67.7M USD +133%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.37M USD
Retained Earnings (Accumulated Deficit) -472M USD -90.4%
Stockholders' Equity Attributable to Parent 1.12B USD +183%
Liabilities and Equity 1.19B USD +180%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -36.1M USD -47.8%
Net Cash Provided by (Used in) Financing Activities 5.99M USD
Net Cash Provided by (Used in) Investing Activities -207M USD -62.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -237M USD -56.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 369M USD +318%
Deferred Tax Assets, Valuation Allowance 101M USD +93.6%
Cash and Cash Equivalents, Period Increase (Decrease) -1.25M USD -131%
Deferred Tax Assets, Gross 101M USD +93.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -222M USD -93.5%
Deferred Tax Assets, Operating Loss Carryforwards 35.1M USD +41.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5K USD +25%
Share-based Payment Arrangement, Expense 51.9M USD +146%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%